Razelle Kurzrock (Razelle Kurkrock)

ORCID

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 130

Top Venues

Cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

Molecular cancer therapeutics

JCO precision oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Vivek Subbiah, Mohamed A Gouda, Bettina Ryll, Howard A Burris, Razelle Kurzrock
The evolving landscape of tissue-agnostic therapies in precision oncology. CA: a cancer journal for clinicians 74 (5) (2024)
Ryuma Tanaka, Kelly Mrachek, Elsa V Arocho-Quinones, Valerie M Carlberg, Candice Smith, Razelle Kurzrock, Tejaswini Deshmukh
Dabrafenib for Pilocytic Astrocytoma With BRAF V599ins . JCO precision oncology 8 (2024)
Mina Nikanjam, Razelle Kurzrock
Critical insights into the evolving drug-approval process in China. Cancer (2024)
Ryuma Tanaka, Kelly Mrachek, Elsa V Arocho-Quinones, Valerie M Carlberg, Candice Smith, Razelle Kurzrock, Tejaswini Deshmukh
Dabrafenib for Pilocytic Astrocytoma With BRAF V599ins . JCO precision oncology 8 (2024)
Mina Nikanjam, Razelle Kurzrock
Critical insights into the evolving drug-approval process in China. Cancer 130 (5) (2024)
Mina Nikanjam, Razelle Kurzrock
Critical insights into the evolving drug-approval process in China. Cancer (2024)
Ashwin V Kammula, Alejandro A Schäffer, Padma Sheila Rajagopal, Razelle Kurzrock, Eytan Ruppin
Outcome differences by sex in oncology clinical trials. Nature communications 15 (1) (2024)
Razelle Kurzrock, David Hong
How to Build a Successful Phase I Clinical Trials Unit: Lessons Based on the MD Anderson Cancer Center Experience. Journal of immunotherapy and precision oncology 7 (3) (2024)
Vivek Subbiah, Mohamed A Gouda, Bettina Ryll, Howard A Burris, Razelle Kurzrock
The evolving landscape of tissue-agnostic therapies in precision oncology. CA: a cancer journal for clinicians (2024)
Megan K D Othus, Sandip P Patel, Young K Chae, Eliana Dietrich, Howard Streicher, Elad Sharon, Razelle Kurzrock
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial. Journal of the National Cancer Institute 116 (5) (2024)
Ashwin V Kammula, Alejandro A Schäffer, Padma Sheila Rajagopal, Razelle Kurzrock, Eytan Ruppin
Outcome differences by sex in oncology clinical trials. Nature communications 15 (1) (2024)
Mina Nikanjam, Razelle Kurzrock
Critical insights into the evolving drug-approval process in China. Cancer 130 (5) (2024)
Megan K D Othus, Sandip P Patel, Young K Chae, Eliana Dietrich, Howard Streicher, Elad Sharon, Razelle Kurzrock
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial. Journal of the National Cancer Institute 116 (5) (2024)
Ashwin V Kammula, Alejandro A Schäffer, Padma Sheila Rajagopal, Razelle Kurzrock, Eytan Ruppin
Outcome differences by sex in oncology clinical trials. Nature communications 15 (1) (2024)
Mina Nikanjam, Razelle Kurzrock
Critical insights into the evolving drug-approval process in China. Cancer 130 (5) (2024)
Petros D Grivas, Elena Garralda, Funda Meric-Bernstam, Ingo K Mellinghoff, Lipika Goyal, James J Harding, Elizabeth C Dees, Rastislav Bahleda, Nilofer S Azad, Asha Karippot, Razelle Kurzrock, Josep Tabernero, Juha Kononen, Matthew Chau Hsien Ng, Rutika Mehta, Nataliya V Uboha, Frédéric Bigot, Valentina Boni, Samantha E Bowyer, Valeriy Breder, Andres Cervantes, Nancy Chan, James M Cleary, Mallika Dhawan, Rikke Helene Løvendahl Eefsen, James Ewing, Donna M Graham, Tormod Kyrre Guren, Jin Won Kim, Krassimir Koynov, Do Youn Oh, Rebecca A Redman, Chia-Jui Yen, David B Spetzler, Marie-Claude Roubaudi-Fraschini, Valérie Nicolas, Rafik Ait-Sarkouh, Claudio Zanna, Abdallah Ennaji, Anna Pokorska-Bocci, Keith T Flaherty
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Megan K D Othus, Sandip P Patel, Young K Chae, Eliana Dietrich, Howard Streicher, Elad Sharon, Razelle Kurzrock
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial. Journal of the National Cancer Institute 116 (5) (2024)
Sana Raoof, Razelle Kurzrock
Turning the Knobs on Screening Liquid Biopsies for High-Risk Populations: Potential for Dialing Down Invasive Procedures. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Megan K D Othus, Sandip P Patel, Young K Chae, Eliana Dietrich, Howard Streicher, Elad Sharon, Razelle Kurzrock
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial. Journal of the National Cancer Institute 116 (5) (2024)
Mina Nikanjam, Razelle Kurzrock
Critical insights into the evolving drug-approval process in China. Cancer 130 (5) (2024)
Mina Nikanjam, Razelle Kurzrock
Critical insights into the evolving drug-approval process in China. Cancer 130 (5) (2024)
Megan K D Othus, Sandip P Patel, Young K Chae, Eliana Dietrich, Howard Streicher, Elad Sharon, Razelle Kurzrock
Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial. Journal of the National Cancer Institute 116 (5) (2024)
Sana Raoof, Razelle Kurzrock
Turning the Knobs on Screening Liquid Biopsies for High-Risk Populations: Potential for Dialing Down Invasive Procedures. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Razelle Kurzrock, David Hong
How to Build a Successful Phase I Clinical Trials Unit: Lessons Based on the MD Anderson Cancer Center Experience. Journal of immunotherapy and precision oncology 7 (3) (2024)
Hirotaka Miyashita, Razelle Kurzrock, Nicholas J Bevins, Kartheeswaran Thangathurai, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Sean T Glenn, Jeffrey M Conroy, Paul DePietro, Eitan Rubin, Jason K Sicklick, Shumei Kato
T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy. NPJ genomic medicine 8 (1) (2023)
Vivek Subbiah, Razelle Kurzrock
Reply to S. Sorscher. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Jason John Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca S Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British journal of cancer (2023)
Umut Disel, Smruthy S Sivakumar, Timothy V Pham, Zoe Fleischmann, R I Anu, Ethan S Sokol, Razelle Kurzrock
Increased KRAS G12C Prevalence, High Tumor Mutational Burden, and Specific Mutational Signatures Are Associated With MUTYH Mutations: A Pan-Cancer Analysis. The oncologist (2023)
Eylül Özgü, Esranur Aydın, Ashkan Adibi, Ünal Metin Tokat, Onur Tutar, Jiancheng Hu, Irem Demiray, Razelle Kurzrock, Mutlu Demiray
Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview. JCO precision oncology 7 (2023)
Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock
Considering molecular alterations as pan-cancer tissue-agnostic targets. Nature cancer 4 (12) (2023)
Justin Shaya, Shumei Kato, Jacob J Adashek, Hitendra Patel, Paul T Fanta, Gregory P Botta, Jason K Sicklick, Razelle Kurzrock
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. NPJ genomic medicine 8 (1) (2023)
Vivek Subbiah, Howard A Burris, Razelle Kurzrock
Revolutionizing cancer drug development: Harnessing the potential of basket trials. Cancer (2023)
Vivek Subbiah, Razelle Kurzrock
Universal Germline and Tumor Genomic Testing Needed to Win the War Against Cancer: Genomics Is the Diagnosis . Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Justin Shaya, Shumei Kato, Jacob J Adashek, Hitendra Patel, Paul T Fanta, Gregory P Botta, Jason K Sicklick, Razelle Kurzrock
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. NPJ genomic medicine 8 (1) (2023)
Jason John Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca S Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British journal of cancer (2023)
Jungah Lim, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J Adashek, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M Conroy, Paul DePietro, Scott M Lippman, Shumei Kato
Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity. Cancer medicine (2023)
Jacob J Adashek, Razelle Kurzrock
Home-run trials for rare cancers: giving the right drug(s) to the right patients at the right time and in the right place. NPJ precision oncology 7 (1) (2023)
Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock
Considering molecular alterations as pan-cancer tissue-agnostic targets. Nature cancer 4 (12) (2023)
Justin Shaya, Shumei Kato, Jacob J Adashek, Hitendra Patel, Paul T Fanta, Gregory P Botta, Jason K Sicklick, Razelle Kurzrock
Personalized matched targeted therapy in advanced pancreatic cancer: a pilot cohort analysis. NPJ genomic medicine 8 (1) (2023)
Jessica Jou, Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro, Mary K Nesline, Jeffrey M Conroy, Eitan Rubin, Ramez N Eskander, Razelle Kurzrock
Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy. Molecular cancer therapeutics (2023)
Jessica Jou, Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro, Mary Nesline, Jeffrey Conroy, Eitan Rubin, Ramez Eskander, Razelle Kurzrock
Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy. Research square (2023)
Jungah Lim, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J Adashek, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M Conroy, Paul DePietro, Scott M Lippman, Shumei Kato
Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity. Cancer medicine (2023)
Eylül Özgü, Esranur Aydın, Ashkan Adibi, Ünal Metin Tokat, Onur Tutar, Jiancheng Hu, Irem Demiray, Razelle Kurzrock, Mutlu Demiray
Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview. JCO precision oncology 7 (2023)
Juan Pablo Hinestrosa, Rosalie C Sears, Harmeet Dhani, Jean M Lewis, Gregor Schroeder, Heath I Balcer, Dove Keith, Brett C Sheppard, Razelle Kurzrock, Paul R Billings
Development of a blood-based extracellular vesicle classifier for detection of early-stage pancreatic ductal adenocarcinoma. Communications medicine 3 (1) (2023)
Jungah Lim, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J Adashek, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M Conroy, Paul DePietro, Scott M Lippman, Shumei Kato
Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity. Cancer medicine (2023)
Jason John Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca S Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British journal of cancer (2023)
Jacob J Adashek, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Pradip De, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M Conroy, Paul DePietro, Scott Lippman, Razelle Kurzrock
LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics. Cancer medicine (2023)
Eylül Özgü, Esranur Aydın, Ashkan Adibi, Ünal Metin Tokat, Onur Tutar, Jiancheng Hu, Irem Demiray, Razelle Kurzrock, Mutlu Demiray
Exceptional Response to MEK Inhibition in a Patient With RAF1-Mutant Myxofibrosarcoma: Case Report and Mechanistic Overview. JCO precision oncology 7 (2023)
Christopher J Sweeney, John D Hainsworth, Ron Bose, Howard A Burris, Razelle Kurzrock, Charles Swanton, Claire F Friedman, David R Spigel, Tania Szado, Katja Schulze, Richard Price, Julia Malato, Amy A Lo, Jonathan Levy, Yong Wang, Wei Yu, Funda Meric-Bernstam
MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2-Altered Advanced Solid Tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Sandip Pravin Patel, Megan K D Othus, Young Kwang Chae, Michael J Dennis, Sarah Gordon, David G Mutch, Wolfram E Samlowski, William R Robinson, Elad Sharon, Christopher Ryan, Gabby Lopez, Melissa Plets, Charles David Blanke, Razelle Kurzrock
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jason John Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca S Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British journal of cancer (2023)
Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock
Considering molecular alterations as pan-cancer tissue-agnostic targets. Nature cancer 4 (12) (2023)
Jessica Jou, Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro, Mary Nesline, Jeffrey Conroy, Eitan Rubin, Ramez Eskander, Razelle Kurzrock
Cancer immunity marker RNA expression levels across gynecologic cancers: Implications for immunotherapy. Research square (2023)
Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock
Considering molecular alterations as pan-cancer tissue-agnostic targets. Nature cancer 4 (12) (2023)
Benedito Arruda Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L Coveler, Steven Francis Powell, Bruno R Bastos, Elizabeth J Davis, Vaibhav Sahai, William Mikrut, James Longstreth, Sheri Smith, Taylor M Weiskittel, Hu Li, Brittany A Borden, Robert Donald Harvey, Solmaz Sahebjam, Andres Cervantes, Austin Koukol, Andrew P Mazar, Neeltje Steeghs, Razelle Kurzrock, Francis J Giles, Pamela N Munster
Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jungah Lim, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J Adashek, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M Conroy, Paul DePietro, Scott M Lippman, Shumei Kato
Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity. Cancer medicine 13 (1) (2023)
Jungah Lim, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J Adashek, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M Conroy, Paul DePietro, Scott M Lippman, Shumei Kato
Pan-cancer analysis of TIM-3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity. Cancer medicine (2023)
Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock
Considering molecular alterations as pan-cancer tissue-agnostic targets. Nature cancer 4 (12) (2023)
Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock
Considering molecular alterations as pan-cancer tissue-agnostic targets. Nature cancer (2023)
Akram Mesleh Shayeb, Razelle Kurzrock, Jacob J Adashek, Shumei Kato
Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies. JCO precision oncology 7 (2023)
Jacob J Adashek, Shumei Kato, Jason K Sicklick, Scott M Lippman, Razelle Kurzrock
Considering molecular alterations as pan-cancer tissue-agnostic targets. Nature cancer 4 (12) (2023)
Lindsey M Charo, Ramez N Eskander, Jason K Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Suzanna Lee, Rupa Subramanian, Richard B Schwab, Rebecca Shatsky, Steven Plaxe, Shumei Kato, Razelle Kurzrock
Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine. JCO precision oncology 6 (2022)
Bryan H Louie, Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Ramez N Eskander, Gregory Botta, Hitendra Patel, Suzanna Lee, Scott M Lippman, Jason K Sicklick, Razelle Kurzrock
Pan-cancer molecular tumor board experience with biomarker-driven precision immunotherapy. NPJ precision oncology 6 (1) (2022)
Amélie Boichard, Razelle Kurzrock
Variable Mutation Expression in Human Cancers: A "Hide-and-Seek" Mechanism Linked to Differential MHC-I Presentation Dynamics. Molecular cancer therapeutics 21 (7) (2022)
Rushikesh S Joshi, Amelie Boichard, Jacob J Adashek, Razelle Kurzrock
High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting. Cancer biology & therapy 23 (1) (2022)
Benjamin Solomon, Ana Callejo, Jair Bar, Guy Berchem, Lyudmila Bazhenova, Pierre Saintigny, Fanny Wunder, Jacques Raynaud, Nicolas Girard, J Jack Lee, Raed Sulaiman, Bruce Prouse, Catherine Bresson, Hila Ventura, Shai Magidi, Eitan Rubin, Brandon Young, Amir Onn, Brian Leyland-Jones, Richard L Schilsky, Vladimir Lazar, Enriqueta Felip, Razelle Kurzrock
A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non-small cell lung cancer. Cancer medicine 11 (14) (2022)
Diviya Gupta, Razelle Kurzrock, Suzanna Lee, Ryosuke Okamura, Hyo Jeong Lim, Ki Hwan Kim, Jason K Sicklick, Shumei Kato
Case series of outcomes in advanced cancer patients with single pathway alterations receiving N-of-One therapies. NPJ precision oncology 6 (1) (2022)
Juan Pablo Hinestrosa, Razelle Kurzrock, Jean M Lewis, Nicholas J Schork, Gregor Schroeder, Ashish M Kamat, Andrew M Lowy, Ramez N Eskander, Orlando Perrera, David Searson, Kiarash Rastegar, Jake R Hughes, Victor Ortiz, Iryna Clark, Heath I Balcer, Larry Arakelyan, Robert Turner, Paul R Billings, Mark J Adler, Scott M Lippman, Rajaram Krishnan
Early-stage multi-cancer detection using an extracellular vesicle protein-based blood test. Communications medicine 2 (2022)
Vladimir Lazar, Nicolas Girard, Eric Raymond, Jean-Francois Martini, Susan Galbraith, Jacques Raynaud, Catherine Bresson, Benjamin Solomon, Shai Magidi, Hovav Nechushtan, Amir Onn, Raanan Berger, Haiquan Chen, Amal Al-Omari, Sadakatsu Ikeda, Ulrik N Lassen, Marina Sekacheva, Enriqueta Felip Font, Josep Tabernero, Gerald Batist, Alan Spatz, Conjeevaram S Pramesh, Philippe Girard, Jean Yves Blay, Thierry Philip, Ioana Berindan Neagoe, Angel Porgador, Eitan Rubin, Razelle Kurzrock, Richard L Schilsky
Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. JCO precision oncology 6 (2022)
Ruchi P Agashe, Scott M Lippman, Razelle Kurzrock
JAK: Not Just Another Kinase. Molecular cancer therapeutics 21 (12) (2022)
Ben George, Razelle Kurzrock
Progression-free survival 2: Is it ready for prime time? Cancer 128 (7) (2022)
Sana Raoof, Razelle Kurzrock
For insights into the real world, consider real-world data. Science translational medicine 14 (673) (2022)
Elena Fountzilas, Apostolia M Tsimberidou, Henry Hiep Vo, Razelle Kurzrock
Clinical trial design in the era of precision medicine. Genome medicine 14 (1) (2022)
Jacob J Adashek, Alexey Goloubev, Shumei Kato, Razelle Kurzrock
Missing the target in cancer therapy. Nature cancer 2 (2021)
Denis Leonardo Fontes Jardim, Sherri Z Millis, Jeffrey S Ross, Michelle Sue-Ann Woo, Siraj M Ali, Razelle Kurzrock
Landscape of Cyclin Pathway Genomic Alterations Across 5,356 Prostate Cancers: Implications for Targeted Therapeutics. The oncologist 26 (4) (2021)
Taylor J Jensen, Aaron M Goodman, Christopher K Ellison, Kimberly A Holden, Shumei Kato, Lisa Kim, Gregory A Daniels, Kerry Fitzgerald, Erin McCarthy, Prachi Nakashe, Amin R Mazloom, Eyad Almasri, Graham McLennan, Daniel S Grosu, Marcia Eisenberg, Razelle Kurzrock
Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible. Molecular cancer therapeutics 20 (11) (2021)
Kristina Mardinian, Jacob J Adashek, Gregory P Botta, Shumei Kato, Razelle Kurzrock
SMARCA4: Implications of an Altered Chromatin-Remodeling Gene for Cancer Development and Therapy. Molecular cancer therapeutics 20 (12) (2021)
Shumei Kato, Caroline Weipert, Sophia Gumas, Ryosuke Okamura, Suzanna Lee, Jason K Sicklick, Jennifer Saam, Razelle Kurzrock
Therapeutic Actionability of Circulating Cell-Free DNA Alterations in Carcinoma of Unknown Primary. JCO precision oncology 5 (2021)
Jacob J Adashek, Filip Janku, Razelle Kurzrock
Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening. Cancers 13 (14) (2021)
Mayra Yebra, Shruti Bhargava, Avi Kumar, Adam M Burgoyne, Chih-Min Tang, Hyunho Yoon, Sudeep Banerjee, Joseph Aguilera, Thekla Cordes, Vipul R Sheth, Sangkyu Noh, Rowan Ustoy, Sam Li, Sunil J Advani, Christopher L Corless, Michael C Heinrich, Razelle Kurzrock, Scott M Lippman, Paul T Fanta, Olivier Harismendy, Christian Metallo, Jason K Sicklick
Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Jacob J Adashek, Razelle Kurzrock
Balancing clinical evidence in the context of a pandemic. Nature biotechnology 39 (3) (2021)
Mina Nikanjam, Jose Tinajero, Donald A Barkauskas, Razelle Kurzrock
BRAF V600E/V600K Mutations versus Nonstandard Alterations: Prognostic Implications and Therapeutic Outcomes. Molecular cancer therapeutics 20 (6) (2021)
Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D Miller, Rashmi Chugh, Scott M Schuetze, Mary D Chamberlin, Barbara J Haley, Anna Maria V Storniolo, Mridula P Reddy, Scott A Anderson, Collin T Zimmerman, Anne P O'Dea, Hamid R Mirshahidi, Jordi Rodon Ahnert, Frank J Brescia, Olwen Hahn, Jane M Raymond, David D Biggs, Roisin M Connolly, Elad Sharon, Larissa A Korde, Robert C Gray, Edward Mayerson, Melissa Plets, Charles D Blanke, Young Kwang Chae, Razelle Kurzrock
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Ryosuke Okamura, Shumei Kato, Suzanna Lee, Rebecca E Jimenez, Jason K Sicklick, Razelle Kurzrock
ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapy. Journal for immunotherapy of cancer 8 (1) (2021)
Sandip Pravin Patel, Edward Mayerson, Young Kwang Chae, Jonathan Strosberg, Jue Wang, Bhavana Konda, Jourdain Hayward, Christine M McLeod, Helen X Chen, Elad Sharon, Megan Othus, Christopher W Ryan, Melissa Plets, Charles D Blanke, Razelle Kurzrock
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer 127 (17) (2021)
Shumei Kato, Jacob J Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E Jimenez, Suzanna Lee, Jason K Sicklick, Razelle Kurzrock
Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (10) (2021)
Ryosuke Okamura, David E Piccioni, Amélie Boichard, Suzanna Lee, Rebecca E Jimenez, Jason K Sicklick, Shumei Kato, Razelle Kurzrock
High prevalence of clonal hematopoiesis-type genomic abnormalities in cell-free DNA in invasive gliomas after treatment. International journal of cancer 148 (11) (2021)
Vladimir Lazar, Shai Magidi, Nicolas Girard, Alexia Savignoni, Jean-François Martini, Giorgio Massimini, Catherine Bresson, Raanan Berger, Amir Onn, Jacques Raynaud, Fanny Wunder, Ioana Berindan Neagoe, Marina Sekacheva, Irene Braña, Josep Tabernero, Enriqueta Felip, Angel Porgador, Claudia Kleinman, Gerald Batist, Benjamin Solomon, Apostolia-Maria Tsimberidou, Jean-Charles Soria, Eitan Rubin, Razelle Kurzrock, Richard L Schilsky
Digital Display Precision Predictor: the prototype of a global biomarker model to guide treatments with targeted therapy and predict progression-free survival. NPJ precision oncology 5 (1) (2021)
Claire F Friedman, John D Hainsworth, Razelle Kurzrock, David R Spigel, Howard A Burris, Christopher J Sweeney, Funda Meric-Bernstam, Yong Wang, Jonathan Levy, Jessica Grindheim, David S Shames, Katja Schulze, Arisha Patel, Charles Swanton
Atezolizumab Treatment of Tumors With High Tumor Mutational Burden From MyPathway, a Multicenter, Open-label, Phase 2a Multiple Basket Study. Cancer discovery (2021)
Mina Nikanjam, Paul Riviere, Aaron Goodman, Donald A Barkauskas, Garrett Frampton, Razelle Kurzrock
Tumor mutational burden is not predictive of cytotoxic chemotherapy response. Oncoimmunology 9 (1) (2020)
Sandy S Bohan, Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Vincent A Miller, Brian Leyland-Jones, Scott M Lippman, Razelle Kurzrock
Attrition of Patients on a Precision Oncology Trial: Analysis of the I-PREDICT Experience. The oncologist 25 (11) (2020)
Hesham M Amin, Ajaykumar C Morani, Najat C Daw, Salah-Eddine Lamhamedi-Cherradi, Vivek Subbiah, Brian A Menegaz, Deeksha Vishwamitra, Ghazaleh Eskandari, Bhawana George, Robert S Benjamin, Shreyaskumar Patel, Juhee Song, Alexander J Lazar, Wei-Lien Wang, Razelle Kurzrock, Alberto Pappo, Peter Meade Anderson, Gary K Schwartz, Dejka Araujo, Branko Cuglievan, Ravin Ratan, David C McCall, Sana Mohiuddin, Jonathan A Livingston, Eric R Molina, Aung Naing, Joseph A Ludwig
IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers 12 (7) (2020)
Amin Haghighat Jahromi, Geraldine Chang, Razelle Kurzrock, Carl K Hoh
Standardized uptake value (SUVmax) in 18F-FDG PET/CT is correlated with the total number of main oncogenic anomalies in cancer patients. Cancer biology & therapy 21 (11) (2020)
Sandip P Patel, Megan Othus, Young Kwang Chae, Francis J Giles, Donna E Hansel, Preet Paul Singh, Annette Fontaine, Manisha H Shah, Anup Kasi Loknath Kumar, Tareq Al Baghdadi, Marc Matrana, Zoran Gatalica, Wolfgang Michael Korn, Jourdain Hayward, Christine McLeod, Helen X Chen, Elad Sharon, Edward Mayerson, Christopher W Ryan, Melissa Plets, Charles D Blanke, Razelle Kurzrock
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (10) (2020)
Paul J Riviere, Aaron M Goodman, Ryosuke Okamura, Donald A Barkauskas, Theresa J Whitchurch, Suzanna Lee, Noor Khalid, Rachel Collier, Manvita Mareboina, Garrett M Frampton, David Fabrizio, Andrew B Sharabi, Shumei Kato, Razelle Kurzrock
High Tumor Mutational Burden Correlates with Longer Survival in Immunotherapy-Naïve Patients with Diverse Cancers. Molecular cancer therapeutics 19 (10) (2020)
Tian Zhang, Sarabjot Pabla, Felicia L Lenzo, Jeffrey M Conroy, Mary K Nesline, Sean T Glenn, Antonios Papanicolau-Sengos, Blake Burgher, Vincent Giamo, Jonathan Andreas, Yirong Wang, Wiam Bshara, Katherine G Madden, Keisuke Shirai, Konstantin Dragnev, Laura J Tafe, Rajan Gupta, Jason Zhu, Matthew Labriola, Shannon McCall, Daniel J George, Pooja Ghatalia, Farshid Dayyani, Robert Edwards, Michelle S Park, Rajbir Singh, Robin Jacob, Saby George, Bo Xu, Matthew Zibelman, Razelle Kurzrock, Carl Morrison
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patients. Oncoimmunology 9 (1) (2020)
Ruchi Agashe, Razelle Kurzrock
Circulating Tumor Cells: From the Laboratory to the Cancer Clinic. Cancers 12 (9) (2020)
Sandip P Patel, Megan Othus, Young Kwang Chae, Razelle Kurzrock, null null
Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Response. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (10) (2020)
Denis L Jardim, Débora De Melo Gagliato, Mina Nikanjam, Donald A Barkauskas, Razelle Kurzrock
Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds. Oncoimmunology 9 (1) (2020)
Alexander V Schperberg, Amélie Boichard, Igor F Tsigelny, Stéphane B Richard, Razelle Kurzrock
Machine learning model to predict oncologic outcomes for drugs in randomized clinical trials. International journal of cancer 147 (9) (2020)

Razelle Kurzrock.css-eqlu8i{font-size:small;padding-left:4px;} (Razelle Kurkrock)

Publication Activity (10 Years)

Top Topics

Top Venues

Razelle Kurzrock (Razelle Kurkrock)